Akademska digitalna zbirka SLovenije - logo

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources SI consortium. For full access, REGISTER.

1 2 3 4
hits: 36
1.
  • Variable mutation expressio... Variable mutation expression in human cancers: A 'hide-and-seek' mechanism linked to differential MHC-I presentation dynamics
    Boichard, Amelie; Kurzrock, Razelle Molecular cancer therapeutics, 07/2022, Volume: 21, Issue: 7
    Journal Article
    Peer reviewed
    Open access

    Not all genomic mutations are expressed at the transcript/protein level, which may explain variation in cancer development, prognosis, and treatment response/resistance. In this study, our aim was to ...
Full text
Available for: NUK, UL, UM, UPUK
2.
Full text

PDF
3.
  • Angiosarcoma heterogeneity ... Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing
    Boichard, Amélie; Wagner, Michael J; Kurzrock, Razelle Genome medicine, 07/2020, Volume: 12, Issue: 1
    Journal Article
    Peer reviewed
    Open access

    Angiosarcoma is an aggressive tumor. Recent case series describe exceptional responses to checkpoint blockade in this disease. Herein, we explored the genomic correlates of 48 angiosarcomas from the ...
Full text
Available for: IZUM, KILJ, NUK, PILJ, PNG, SAZU, UL, UM, UPUK

PDF
4.
  • High expression of PD-1 lig... High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
    Boichard, Amélie; Tsigelny, Igor F.; Kurzrock, Razelle Oncoimmunology, 03/2017, Volume: 6, Issue: 3
    Journal Article
    Peer reviewed
    Open access

    Immunotherapy with checkpoint inhibitors, such as antibodies blocking the programmed cell-death receptor-1 (PD-1), has resulted in remarkable responses in patients having traditionally refractory ...
Full text
Available for: NUK, UL, UM, UPUK

PDF
5.
  • Mutated TP53 is a marker of... Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues
    Li, Alex M.; Boichard, Amélie; Kurzrock, Razelle Cancer biology & therapy, 01/2020, Volume: 21, Issue: 1
    Journal Article
    Peer reviewed
    Open access

    Anti-angiogenic therapies are an important class of anti-cancer treatment drugs. However, their efficacy is limited to certain tumors and would benefit from identifying a biomarker predictive of ...
Full text
Available for: NUK, UL, UM, UPUK

PDF
6.
  • Role of ultraviolet mutatio... Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
    Pham, Timothy V.; Boichard, Amélie; Goodman, Aaron ... Molecular oncology, August 2020, Volume: 14, Issue: 8
    Journal Article
    Peer reviewed
    Open access

    Hydrophobic neoantigens are more immunogenic because they are better presented by the major histocompatibility complex and better recognized by T cells. Tumor cells can evade the immune response by ...
Full text
Available for: FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SAZU, SBCE, SBMB, UL, UM, UPUK

PDF
7.
  • Circulating Cell-Free Tumor... Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
    Jovelet, Cécile; Ileana, Ecaterina; Le Deley, Marie-Cécile ... Clinical cancer research, 06/2016, Volume: 22, Issue: 12
    Journal Article
    Peer reviewed
    Open access

    Liquid biopsies based on circulating cell-free DNA (cfDNA) analysis are described as surrogate samples for molecular analysis. We evaluated the concordance between tumor DNA (tDNA) and cfDNA analysis ...
Full text
Available for: CMK, NUK, UL, UM, UPUK

PDF
8.
  • Therapeutic implications of... Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden
    Boichard, Amélie; Lippman, Scott M; Kurzrock, Razelle Journal of hematology & oncology, 12/2021, Volume: 14, Issue: 1
    Journal Article
    Peer reviewed
    Open access

    Amplifications of oncogenic genes are often considered actionable. However, not all patients respond. Questions have therefore arisen regarding the degree to which amplifications, especially ...
Full text
Available for: IZUM, KILJ, NUK, PILJ, PNG, SAZU, UL, UM, UPUK

PDF
9.
  • New therapeutic approaches ... New therapeutic approaches to overcoming resistant EGFR exon 20 alterations
    Li, Alex M.; Boichard, Amélie; Felip, Enriqueta ... Critical reviews in oncology/hematology, 07/2020, Volume: 151
    Journal Article
    Peer reviewed
    Open access

    Display omitted •Some EGFR exon 20 alterations confer resistance to several EGFR inhibitors.•Poziotinib is able to target the small kinase pocket created by exon 20 insertions.•EGFR exon 20 ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
10.
  • High prevalence of clonal h... High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment
    Okamura, Ryosuke; Piccioni, David E.; Boichard, Amélie ... International journal of cancer, 1 June 2021, Volume: 148, Issue: 11
    Journal Article
    Peer reviewed
    Open access

    Plasma cell‐free DNA (cfDNA) is emerging as an important diagnostic tool in cancer. However, cfDNA alterations may differ from those in tissue and sometimes may reflect processes unrelated to the ...
Full text
Available for: BFBNIB, FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SAZU, SBCE, SBMB, UL, UM, UPUK

PDF
1 2 3 4
hits: 36

Load filters